Search academic texts

Information × Registration Number 0217U000443, 0116U003574 , R & D reports Title The role of BCR/ABL gene mutations, chromosome, molecular genetic abnormalities and immunogenetic parameters in formation of approaches to optimization of target therapy in patients with chronic myeloid leukemia in the remote period after the Chornobyl power plant accident. popup.stage_title Head Dyagil I.S., Minchenko J.M., Registration Date 03-02-2017 Organization State institution "National research centеr for radiation medicine of the National academy of medical sciences of Ukraine " popup.description2 The object of study - patients with chronic myeloid leukemia who have achieved deep molecular response to imatinib therapy. Objective - to determine the clinical features, as well as chromosomal abnormalities, the dynamics of BCR/ABL gene expression and immunogenetic parameters in patients with chronic myeloid leukemia who have achieved deep molecular response on the therapy of tyrosine kinase inhibitors. Methods - hematologic, cytogenetic, molecular genetic, immunogenetic, culture and statistics. The results. The study involved 48 patients with CML who have reached deep molecular response on tyrosine kinase inhibitors therapy. It was found that the cumulative incidence of deep molecular response was significantly higher in patients with CML without splenomegaly and the number of white blood cells under 100 G /l compared with patients with severe splenomegaly and leukocytes above 100 G /l (p <0.05). It has been determined that the presence of the transcript e14a2 is a favorable prognostic factor for achieving deep molecular response in patients with CML on imatinib. Achieving a complete cytogenetic response at 3 months of therapy was associated with a high probability of achieving deep molecular response to imatinib therapy in the next 24 months of treatment. It has been shown that patients with rate of BCR /ABL1 gene expression under 1% at the 3rd month of imatinib therapy had a significantly higher cumulative incidence of deep molecular response after 2 years of treatment compared with patients with BCR /ABL1 rate above 1% at the same time. The level of BCR/ABL1 <= 0,1% at 6 months of imatinib therapy had a favorable prognostic significance for achieving deep molecular response to imatinib therapy at 24 months of treatment. High cumulative incidence of deep molecular response at 2 years of therapy persisted in patients who had major molecular response at 12 months of treatment (p <0.001). It was determined that a deep molecular response was associated with better 5-year event-free survival compared to patients who have been registered only a complete cytogenetic response (93% vs. 50%, p <0.001), and compared to patients who achieved complete cytogenetic and major molecular response to imatinib therapy (93% vs. 69%, p <0.001). There was no association of ABO and Rh systems phenotypes with the maintenance of deep molecular response to tyrosine kinase inhibitors therapy at the level of antigenic structures specificities, indicating the absence of selective selection in favor of a particular phenotype. There was defined the factors associated with the maintainece of deep molecular response to tyrosine kinase inhibitors treatment in CML patients: at the time of diagnosis - chronic phase CML, the absence of splenomegaly, leukocytosis under 100 G/l, no additional to translocation t(9;22)(q34;q11) chromosomal abnormalities, gene transcript BCR/ABL1 e14a2; during the monitoring - at 3 month of imatinib therapy - the achievement of a complete cytogenetic response and rate of BCR / ABL1 <= 1%, at 6 month of therapy - rate of BCR/ABL1 <= 0,1%, raising the level and concentration of IFN-gamma and IL-2. Product Description popup.authors Балан Валентина Володимирівна Дмитренко Ірина Віталіївна Дмитренко Олена Олександрівна Малінкіна Тетяна Володимирівна Мартіна Зоя Володимирівна Парамонов Віктор Володимирович Федоренко Віра Григорівна Шляхтиченко Тетяна Юрівна Шолойко Валентина Василівна popup.nrat_date 2020-04-02 Close